The impact of influenza infection is felt globally each yearwhen the disease develops in approximately 20 percent of theworld's population. In the United States, influenza infectionsoccur in epidemics each winter, generally between late Decemberand early March. Recent events, including human cases of avianinfluenza, have heightened awareness of the threat of a pandemicand have spurred efforts to develop plans for its control.
Although vaccination is the primary strategy for the preventionof influenza, there are a number of likely scenarios for whichvaccination is inadequate and effective antiviral agents wouldbe of the utmost importance. . . . [Full Text of this Article]
Adamantanes and Neuraminidase Inhibitors
Development of Neuraminidase Inhibitor Molecules
Pharmacokinetics
Clinical Trials of Zanamivir and Oseltamivir
Treatment of Healthy Adults
Therapy in the Elderly
Therapy in Children
Prophylactic Efficacy of Zanamivir and Oseltamivir
Prophylaxis in Healthy Adults
Prophylaxis in High-Risk Elderly or Chronically Ill Populations
Prophylaxis in Children after Exposure
Safety and Dosage of Neuraminidase Inhibitors
Resistance to the Neuraminidase Inhibitors
Strategies for Treatment
Strategies for Prophylaxis
Avian Influenza and Pandemic Planning
Source Information
From the Departments of Pediatrics and Microbiology and Immunology, Weill Medical College of Cornell University, New York.
Address reprint requests to Dr. Moscona at the Department of Pediatrics, Box 309, Weill Medical College of Cornell University, 515 E. 71st St., Suite 600D, New York, NY 10021, or at anm2047@med.cornell.edu.
This article has been cited by other articles:
Zeng, Q., Langereis, M. A., van Vliet, A. L. W., Huizinga, E. G., de Groot, R. J.
(2008). Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc. Natl. Acad. Sci. USA
105: 9065-9069
[Abstract][Full Text]
Huang, I-C., Li, W., Sui, J., Marasco, W., Choe, H., Farzan, M.
(2008). Influenza A Virus Neuraminidase Limits Viral Superinfection. J. Virol.
82: 4834-4843
[Abstract][Full Text]
Nicoll, A
(2008). Children, avian influenza H5N1 and preparing for the next pandemic. Arch. Dis. Child.
93: 433-438
[Abstract][Full Text]
Carter, M. J.
(2007). A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza. J Med Microbiol
56: 875-883
[Abstract][Full Text]
Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Koike, K., Mitamura, K., Kawaoka, Y.
(2007). Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase Inhibitors. JAMA
297: 1435-1442
[Abstract][Full Text]
Moscona, A., McKimm-Breschkin, J.
(2007). News About Influenza B Drug Resistance That Cannot Be Ignored. JAMA
297: 1492-1493
[Full Text]
Aruksakunwong, O., Malaisree, M., Decha, P., Sompornpisut, P., Parasuk, V., Pianwanit, S., Hannongbua, S.
(2007). On the Lower Susceptibility of Oseltamivir to Influenza Neuraminidase Subtype N1 than Those in N2 and N9. Biophys. J
92: 798-807
[Abstract][Full Text]
Skowronski, D. M., Li, Y., Tweed, S. A., Tam, T. W.S., Petric, M., David, S. T., Marra, F., Bastien, N., Lee, S. W., Krajden, M., Brunham, R. C.
(2007). Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada. CMAJ
176: 47-53
[Abstract][Full Text]
Rameix-Welti, M. A., Agou, F., Buchy, P., Mardy, S., Aubin, J. T., Veron, M., van der Werf, S., Naffakh, N.
(2006). Natural Variation Can Significantly Alter the Sensitivity of Influenza A (H5N1) Viruses to Oseltamivir. Antimicrob. Agents Chemother.
50: 3809-3815
[Abstract][Full Text]
Ge, Q., Pastey, M., Kobasa, D., Puthavathana, P., Lupfer, C., Bestwick, R. K., Iversen, P. L., Chen, J., Stein, D. A.
(2006). Inhibition of Multiple Subtypes of Influenza A Virus in Cell Cultures with Morpholino Oligomers. Antimicrob. Agents Chemother.
50: 3724-3733
[Abstract][Full Text]
Gillim-Ross, L., Subbarao, K.
(2006). Emerging Respiratory Viruses: Challenges and Vaccine Strategies. Clin. Microbiol. Rev.
19: 614-636
[Abstract][Full Text]
Singh, A M, Busse, W W
(2006). Asthma exacerbations {middle dot} 2: Aetiology.. Thorax
61: 809-816
[Abstract][Full Text]
Bartlett, J. G.
(2006). Planning for Avian Influenza. ANN INTERN MED
145: 141-144
[Abstract][Full Text]
Regoes, R. R., Bonhoeffer, S.
(2006). Emergence of drug-resistant influenza virus: population dynamical considerations.. Science
312: 389-391
[Abstract][Full Text]
Germann, T. C., Kadau, K., Longini, I. M. Jr., Macken, C. A.
(2006). From the Cover: Mitigation strategies for pandemic influenza in the United States. Proc. Natl. Acad. Sci. USA
103: 5935-5940
[Abstract][Full Text]
(2006). High Levels of Adamantane Resistance Among Influenza A (H3N2) Viruses and Interim Guidelines for Use of Antiviral Agents--United States, 2005-06 Influenza Season. JAMA
295: 881-882
[Full Text]
Weinstock, D. M., Zuccotti, G.
(2006). Adamantane Resistance in Influenza A. JAMA
295: 934-936
[Full Text]
Gostin, L. O.
(2006). Medical Countermeasures for Pandemic Influenza: Ethics and the Law. JAMA
295: 554-556
[Full Text]
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J.D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., Peiris, J.S. M., Hien, T. T., Farrar, J.
(2005). Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection. NEJM
353: 2667-2672
[Abstract][Full Text]
Tanne, J. H.
(2005). Roche considers licensing companies to make oseltamivir. BMJ
331: 981-981
[Full Text]
Macfarlane, J. T, Lim, W. S.
(2005). Bird flu and pandemic flu. BMJ
331: 975-976
[Full Text]